Objective: Lumateperone is an FDA-approved atypical antipsychotic to treat schizophrenia, bipolar I or II depression, and major depressive disorder (MDD). Post hoc analyses of a randomized, phase 3, double-blind, placebo-controlled trial (Study 501) evaluated the efficacy of lumateperone 42 mg adjunctive to antidepress...
S. Durgam, W. Earley, R. Migliore et al.· The Primary Care Companion F...· 0 citations
ECT was associated with a statistically significant improvement in anhedonia among adults with MDD, and future ECT studies should assess anhedonia as an outcome, while using a validated anhedonia measure.
Ryan Radmard, Kristoffer J. Panganiban, Angela T. H. Kwan et al.· Journal of Affective Disorde...· 0 citations
BACKGROUND
Anhedonia is a debilitating core feature of mood disorders, and is associated with significant functional impairment and poor quality of life. Psilocybin has recently emerged as a novel antidepressant treatment in major depressive disorder (MDD), however, its effects on anhedonia specifically have yet to be...
Erica S. Kaczmarek, Sabrina Wong, Noah Chisamore et al.· Journal of Psychiatric Resea...· 0 citations
Ketamine has shown rapid antidepressant effects in treatment-resistant mood disorders; however, the durability of these benefits during maintenance treatment remains unclear. This systematic review evaluated outcomes associated with repeated ketamine and esketamine administration during the maintenance phase of treatme...
Shreya Vasudeva, Diana K. Orsini, Gabrielle F. M. Lovell et al.· Psychiatry Research· 0 citations
Weight gain and impaired glucose metabolism are common complications of antipsychotic treatment in schizophrenia spectrum disorders (SSD). While beneficial in other populations, the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in SSD remain unclear. We conducted a systematic review and m...
A. Gędek, Szymon Modrzejewski, Krzysztof Polański et al.· European Neuropsychopharmaco...· 0 citations
Findings indicate region- and context-specific differences in cortical hemodynamic responses and functional coupling in individuals with BD during EE processing may serve as candidate features for further investigation in larger and independent studies.
Cui-Yan Wang, Yue-Qian Zhang, Wei Zhang et al.· Asian Journal of Psychiatry· 0 citations
BACKGROUND
Many proteins integral to psychotropic agents' pharmacokinetics (PK) and pharmacodynamics (PD) exhibit circadian variation in expression and function. Chronopharmacology examines the effect of circadian systems on the pharmacology of drugs. Herein, we review the impact of circadian rhythm on drug-metabolizin...
Victoria Yue Tan, Sabrina Wong, Gia-Han Le et al.· Journal of Psychopharmacolog...· 0 citations
With psychometric validation underway, the TGI-3S offers an anamnesis-embedded, brief, yet comprehensive tool for facilitating the assessment of somatic health in patients with mental disorders.
R. McIntyre, Á. Barabássy, Z. Dombi et al.· European psychiatry· 0 citations
Current evidence supports the safety of ketamine and esketamine for TRD, with no cumulative organ toxicity or iatrogenic addiction during maintenance treatment, but findings are limited by heterogeneity in safety monitoring across studies.
Tychique T. Wasolua, Morgan Hardy, Tanner J. Bommersbach et al.· Psychotherapy and Psychosoma...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.